News

News

1/25/2016

New IMS Report highlights the importance of biosimilar competition on patient access and treatment costs

New IMS Report highlights the importance of biosimilar competition on patient access and treatment costs

A new report, “The Impact of Biosimilars Competition,” which was prepared by IMS Health for the European Commission services, together with the summary of the “Workshop on Access to and Uptake of Biosimilar Medicinal Products” of October 6, 2015, has now been published and is welcomed by the European pharmaceutical industry.

Source: The Pharma Letter